Progress in neuro-psychopharmacology & biological psychiatry · 2008
Extended release carbamazepine in the treatment of pathological gambling: an open-label study.
Клиническое исследованиеСтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Black Donald W, Shaw Martha C, Allen Jeff
Аннотация
BACKGROUND: The efficacy and tolerability of extended release carbamazepine was tested in the treatment of pathological gambling (PG).
METHOD: Non-depressed outpatients with DSM-IV PG received flexibly dosed extended release carbamazepine in a prospective 10-week open-label trial following a two-week observation period. Subjects were evaluated at baseline and at one week intervals during a four week titration period, and every two weeks thereafter for assessment of gambling behavior, mood, and adverse experiences. The primary efficacy measure was the Yale-Brown Obsessive-Compulsive Scale modified for PG (YBOCS-PG).
RESULTS: Eight subjects (6 men, 2 women) had at least one post-baseline visit, and five subjects (63%) completed the protocol. Significant improvement was found on the YBOCS-PG (P< .001). Seven of the eight subjects with post-baseline assessment (88%) were considered responders (i.e., achieved "much" or "very much" improvement on the CGI). Four subjects (50%) abstained from gambling during their final month of study participation. Several patients were dropped because of adverse experiences.
CONCLUSION: The results suggest that extended release carbamazepine may be effective in the treatment of PG.
METHOD: Non-depressed outpatients with DSM-IV PG received flexibly dosed extended release carbamazepine in a prospective 10-week open-label trial following a two-week observation period. Subjects were evaluated at baseline and at one week intervals during a four week titration period, and every two weeks thereafter for assessment of gambling behavior, mood, and adverse experiences. The primary efficacy measure was the Yale-Brown Obsessive-Compulsive Scale modified for PG (YBOCS-PG).
RESULTS: Eight subjects (6 men, 2 women) had at least one post-baseline visit, and five subjects (63%) completed the protocol. Significant improvement was found on the YBOCS-PG (P< .001). Seven of the eight subjects with post-baseline assessment (88%) were considered responders (i.e., achieved "much" or "very much" improvement on the CGI). Four subjects (50%) abstained from gambling during their final month of study participation. Several patients were dropped because of adverse experiences.
CONCLUSION: The results suggest that extended release carbamazepine may be effective in the treatment of PG.